檢索結果 - Eric J. Feldman

  • Showing 1 - 20 results of 20
Refine Results
  1. 1
    The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase

    The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase 由 XU Wen-qing, Karen Seiter, Eric J. Feldman, Tauseef Ahmed, JW Chiao

    出版 1996
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide

    Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide 由 Gail J. Roboz, Ellen K. Ritchie, Rebecca F. Carlin, Michael S. Samuel, Leanne Gale, Juliette L. Provenzano-Gober, Tania J. Curcio, Eric J. Feldman, Paul Kligfield

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia

    Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia 由 Bethan Psaila, James B. Bussel, Andrew L. Frelinger, Bracken Babula, Matthew D. Linden, Y. LI, M.R. BARNARD, Christian Tate, Eric J. Feldman, Alan D. Michelson

    出版 2011
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

    Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia 由 Ellen K. Ritchie, Eric J. Feldman, Paul J. Christos, Sarah D. Rohan, Catherine B. Lagassa, Cindy Ippoliti, Joseph M. Scandura, Karen-Sue Carlson, Gail J. Roboz

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death

    The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death 由 Isabelle Petit, Matthias A. Karajannis, Loi͏̈c Vincent, Lauren M. Young, Jason M. Butler, Andrea T. Hooper, Koji Shido, Hermann Steller, David J. Chaplin, Eric J. Feldman, Shahin Rafii

    出版 2007
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

    Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia 由 Daniel J. DeAngelo, Brian A. Jonas, Jane L. Liesveld, Dale L. Bixby, Anjali S. Advani, Paula Marlton, John L. Magnani, Helen Thackray, Eric J. Feldman, Michael O’Dwyer, Pamela S. Becker

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

    First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leuk... 由 Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Ellen K. Ritchie, Gail J. Roboz, Alan F. List, Steven L. Allen, Ekatherine Asatiani, Lawrence D. Mayer, Christine E. Swenson, Arthur C. Louie

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

    Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML 由 Joseph M. Scandura, Gail J. Roboz, Michelle Moh, Ewelina Morawa, Fabienne Brenet, Jahar R Bose, Luis Juárez Villegas, Usama Gergis, Sebastian Mayer, Cindy Ippoliti, Tania J. Curcio, Ellen K. Ritchie, Eric J. Feldman

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias 由 Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

    Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML 由 Jorge E. Cortés, Stuart L. Goldberg, Eric J. Feldman, David Rizzeri, Donna E. Hogge, Melissa L. Larson, Arnaud Pigneux, Christian Récher, Gary J. Schiller, Krzysztof Warzocha, Hagop M. Kantarjian, Arthur C. Louie, Jonathan E. Kolitz

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

    Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML 由 Jeffrey E. Lancet, Jorge E. Cortés, Donna E. Hogge, Martin S. Tallman, Tibor Kovacsovics, Lloyd E. Damon, Rami S. Komrokji, Scott R. Solomon, Jonathan E. Kolitz, Maureen Cooper, Andrew M. Yeager, Arthur C. Louie, Eric J. Feldman

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

    Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myel... 由 John Mascarenhas, Mark Heaney, Vesna Najfeld, Elizabeth O. Hexner, Omar Abdel‐Wahab, Raajit K. Rampal, Farhad Ravandi, Bruce Petersen, Gail J. Roboz, Eric J. Feldman, Nikolai A. Podoltsev, Dan Douer, Ross L. Levine, Martin S. Tallman, Ronald Hoffman

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

    A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia 由 Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline M. Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence E. Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett‐Mayer, Peter L. Greenberg, James R. Wright, Judith E. Karp

    出版 2006
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

    Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion 由 Alan F. List, Gordon W. Dewald, John M. Bennett, Aristoteles Giagounidis, Azra Raza, Eric J. Feldman, Bayard L. Powell, Peter L. Greenberg, Deborah A. Thomas, Richard M. Stone, Craig B. Reeder, Kenton Wride, John Patin, M. Schmidt, Jerome B. Zeldis, Robert Knight

    出版 2006
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

    Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies 由 Peter Martin, Amy Chadburn, Paul J. Christos, Richard R. Furman, Jia Ruan, Malea Joyce, E Fusco, Patricia Glynn, Rebecca Elstrom, Rubén Niesvizky, Eric J. Feldman, Tsiporah B. Shore, Michael W. Schuster, Scott Ely, D M Knowles, Selina Chen‐Kiang, Morton Coleman, John P. Leonard

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

    Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-R... 由 Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo, Ilene Galinsky, Elihu H. Estey, Carlo Lanza, Edward Fox, Gerhard Ehninger, Eric J. Feldman, Gary J. Schiller, Virginia M. Klimek, Stephen D. Nimer, D. Gary Gilliland, Catherine Dutreix, Alice Huntsman-Labed, J. D. Virkus, Francis J. Giles

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

    Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refrac... 由 Eric J. Feldman, Joseph Brandwein, Richard M. Stone, Matt Kalaycio, Joseph O. Moore, Julie O’Connor, Nancy Wedel, Gail J. Roboz, Carole B. Miller, Raj Chopra, Joseph C. Jurcic, Randy A. Brown, W. Christopher Ehmann, Philip Schulman, Stanley R. Frankel, Daniel De Angelo, David A. Scheinberg

    出版 2005
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

    Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain 由 Florian H. Heidel, Fian K. Solem, Frank Breitenbuecher, Daniel B. Lipka, Stefan Kasper, Melanie Thiede, Christian Brandts, Hubert Serve, Johannes Roesel, Francis J. Giles, Eric J. Feldman, Gerhard Ehninger, Gary J. Schiller, Stephen D. Nimer, Richard M. Stone, Yanfeng Wang, Thomas Kindler, Pamela Cohen, Christoph Huber, Thomas Fischer

    出版 2005
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q 由 Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah A. Thomas, Robert Knight, M. Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

    Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia 由 Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere‐Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman, Dennis R. Benjamin

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: